Patents by Inventor Chandeshwari Chilampalli
Chandeshwari Chilampalli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230390218Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: ApplicationFiled: August 22, 2023Publication date: December 7, 2023Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Patent number: 11771663Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: March 2, 2021Date of Patent: October 3, 2023Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Patent number: 11744811Abstract: The present invention is directed to methods of stabilizing a pharmaceutical composition comprising epinephrine containing the steps filling a container, capping the container, assembling the container and placing the assembled capped container (assembled device) in a secondary packaging system.Type: GrantFiled: June 30, 2021Date of Patent: September 5, 2023Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Eshwaran Narayanan, Rajesh Wakaskar, Chandeshwari Chilampalli, Thrimoorthy Potta, Venkat R. Goskonda
-
Publication number: 20230181457Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: ApplicationFiled: February 14, 2023Publication date: June 15, 2023Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 11628139Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: GrantFiled: March 11, 2021Date of Patent: April 18, 2023Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 11617713Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: GrantFiled: March 11, 2021Date of Patent: April 4, 2023Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 11571384Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: June 13, 2018Date of Patent: February 7, 2023Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Publication number: 20230008410Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: ApplicationFiled: August 25, 2021Publication date: January 12, 2023Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 11517525Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: June 13, 2018Date of Patent: December 6, 2022Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Publication number: 20210353533Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: ApplicationFiled: March 11, 2021Publication date: November 18, 2021Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Publication number: 20210338604Abstract: The present invention is directed to methods of stabilizing a pharmaceutical composition comprising epinephrine containing the steps filling a container, capping the container, assembling the container and placing the assembled capped container (assembled device) in a secondary packaging system.Type: ApplicationFiled: June 30, 2021Publication date: November 4, 2021Inventors: Eshwaran Narayanan, Rajesh Wakaskar, Chandeshwari Chilampalli, Thrimoorthy Potta, Venkat R. Goskonda
-
Patent number: 11135155Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: GrantFiled: October 31, 2018Date of Patent: October 5, 2021Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 11077075Abstract: The present invention is directed to methods of stabilizing a pharmaceutical composition comprising epinephrine containing the steps filling a container, capping the container, assembling the container and placing the assembled capped container (assembled device) in a secondary packaging system.Type: GrantFiled: January 8, 2019Date of Patent: August 3, 2021Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Eshwaran Narayanan, Rajesh Wakaskar, Chandeshwari Chilampalli, Thrimoorthy Potta, Venkat R. Goskonda
-
Publication number: 20210196625Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: ApplicationFiled: March 11, 2021Publication date: July 1, 2021Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Publication number: 20210177777Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: ApplicationFiled: March 2, 2021Publication date: June 17, 2021Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Patent number: 10973814Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: GrantFiled: November 5, 2019Date of Patent: April 13, 2021Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 10973781Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: March 1, 2019Date of Patent: April 13, 2021Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Patent number: 10966925Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: January 4, 2019Date of Patent: April 6, 2021Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Patent number: 10617637Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: June 29, 2018Date of Patent: April 14, 2020Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Publication number: 20200093818Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: ApplicationFiled: November 5, 2019Publication date: March 26, 2020Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda